Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar kannankeril (71.77) Submitted: 8/29/2010 11:35:04 PM : Outperform Start Price: $1.98 DYAX Score: -17.29

I believe the stock price has reached a floor. Institutions & insiders have started buying in large quantities.
I like betting with insiders who have a stake in the game.

Featured Broker Partners


Advertisement